Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.

@article{Gldenpfennig2005SafetyTA,
  title={Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.},
  author={Werner M G{\"u}ldenpfennig and Kathryn H Poole and Kenneth W. Sommerville and Babak Boroojerdi},
  journal={Clinical neuropharmacology},
  year={2005},
  volume={28 3},
  pages={106-10}
}
Rotigotine is a new dopamine agonist with transdermal patch formulation for the treatment of Parkinson disease. The aim of this study was to investigate safety and efficacy of rotigotine in patients with early-stage Parkinson disease. In this open-label, dose-escalation, safety and efficacy study, 31 patients in the early stages of idiopathic Parkinson disease received rotigotine to a maximum of 18.0 mg/day. Of the 29 patients who completed the 28-day treatment phase, 24 were maintained at the… CONTINUE READING